After a two-month battle, OSI Pharmaceuticals said on Sunday that it had agreed to sell itself to Astellas Pharma of Japan for US$4 billion in cash, after its suitor raised its takeover offer.
Under the terms of the deal, OSI shareholders will receive US$57.50 a share, a 55 percent premium to OSI’s share price on Feb. 26, the last trading day before Astellas made its first takeover bid public in March.
The new price is 10.5 percent higher than Astellas’ first proposal of US$52 a share.
The sale ends a standoff over OSI, a biotechnology company whose main product is Tarceva, a drug used to treat several kinds of cancer in conjunction with chemotherapy.
Astellas initially unveiled a US$3.5 billion unsolicited offer in March, which OSI rejected soon after.
After Astellas began a tender offer for OSI’s shares and proposed a rival slate of directors, the US drug maker agreed to open its books to its unsolicited suitor.
Analysts have said that they expected Astellas to prevail, especially given an apparent paucity of rival bidders. But they expected that Astellas would need to raise its bid.
Shares in OSI closed on Friday at US$59.80, up nearly 4.5 percent, as investors expected Astellas to raise its offer for the company. OSI’s stock has risen 61.5 percent since Astellas made its first takeover proposal.
Colin Goddard, OSI’s chief executive, said in a statement: “We believe today’s announcement recognizes the significant value we have built for our stockholders while providing the merged companies the opportunity to forge a stronger collective path forward in a shared mission to provide innovative new medicines to patients around the world.”
Founded in 1983 and based in Melville, New York, OSI’s main product is Tarceva, primarily used to treat lung cancer. The drug generated US$1.2 billion in sales last year. OSI has sought to expand Tarceva’s use in cancer treatment.
The company reported US$75.9 million in net income last year, on US$428.1 million in revenue. It has 524 employees.
Astellas, based in Tokyo and one of Japan’s biggest drug makers, has made it clear that a priority was expanding its oncology drug pipeline.
The deal is a successful effort by Astellas to buy a US biotech company, after losing a battle over CV Therapeutics last year to Gilead Sciences.
“The merger with OSI provides Astellas with a top tier oncology platform in the US and an expanded product portfolio and pipelines,” Astellas chief executive Masafumi Nogimori said in a statement.
The government is aiming to recruit 1,096 foreign English teachers and teaching assistants this year, the Ministry of Education said yesterday. The foreign teachers would work closely with elementary and junior-high instructors to create and teach courses, ministry official Tsai Yi-ching (蔡宜靜) said. Together, they would create an immersive language environment, helping to motivate students while enhancing the skills of local teachers, she said. The ministry has since 2021 been recruiting foreign teachers through the Taiwan Foreign English Teacher Program, which offers placement, salary, housing and other benefits to eligible foreign teachers. Two centers serving northern and southern Taiwan assist in recruiting and training
WIDE NET: Health officials said they are considering all possibilities, such as bongkrekic acid, while the city mayor said they have not ruled out the possibility of a malicious act of poisoning Two people who dined at a restaurant in Taipei’s Far Eastern Department Store Xinyi A13 last week have died, while four are in intensive care, the Taipei Department of Health said yesterday. All of the outlets of Malaysian vegetarian restaurant franchise Polam Kopitiam have been ordered to close pending an investigation after 11 people became ill due to suspected food poisoning, city officials told a news conference in Taipei. The first fatality, a 39-year-old man who ate at the restaurant on Friday last week, died of kidney failure two days later at the city’s Mackay Memorial Hospital. A 66-year-old man who dined
‘CARRIER KILLERS’: The Tuo Chiang-class corvettes’ stealth capability means they have a radar cross-section as small as the size of a fishing boat, an analyst said President Tsai Ing-wen (蔡英文) yesterday presided over a ceremony at Yilan County’s Suao Harbor (蘇澳港), where the navy took delivery of two indigenous Tuo Chiang-class corvettes. The corvettes, An Chiang (安江) and Wan Chiang (萬江), along with the introduction of the coast guard’s third and fourth 4,000-tonne cutters earlier this month, are a testament to Taiwan’s shipbuilding capability and signify the nation’s resolve to defend democracy and freedom, Tsai said. The vessels are also the last two of six Tuo Chiang-class corvettes ordered from Lungteh Shipbuilding Co (龍德造船) by the navy, Tsai said. The first Tuo Chiang-class vessel delivered was Ta Chiang (塔江)
EYE ON STRAIT: The US spending bill ‘doubles security cooperation funding for Taiwan,’ while also seeking to counter the influence of China US President Joe Biden on Saturday signed into law a US$1.2 trillion spending package that includes US$300 million in foreign military financing to Taiwan, as well as funding for Taipei-Washington cooperative projects. The US Congress early on Saturday overwhelmingly passed the Further Consolidated Appropriations Act 2024 to avoid a partial shutdown and fund the government through September for a fiscal year that began six months ago. Under the package, the Defense Appropriations Act would provide a US$27 billion increase from the previous fiscal year to fund “critical national defense efforts, including countering the PRC [People’s Republic of China],” according to a summary